Agilent Receives FDA Approval for PD-L1 IHC 28-8 pharmDx in Esophageal Squamous Cell Carcinoma (ESCC), Gastric, Gastroesophageal Junction (GEJ), and Esophageal Adenocarcinoma
Go back to Agilent Receives FDA Approval for PD-L1 IHC 28-8 pharmDx in Esophageal Squamous Cell Carcinoma (ESCC), Gastric, Gastroesophageal Junction (GEJ), and Esophageal Adenocarcinoma| Agilent Technologies Inc (NYSE: A) | Delayed: 150.86 +0.88 (0.59%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $149.98 | 52 Week High | $48.63 | |||
| Open | $148.97 | 52 Week Low | $34.15 | |||
| Day High | $151.59 | P/E | 69.84 | |||
| Day Low | $147.78 | EPS | $2.16 | |||
| Volume | 1,825,451 | |||||
